The absence of p21(Cip1/WAF1) alters keratinocyte growth and differentiation and promotes ras-tumor progression

Genes and Development

Volumn 10, Issue 23, 1996, Pages 3065-3075

  Missero, Caterina ^a   Di Cunto, Ferdinando ^a   Kiyokawa, Hiroaki ^b   Koff, Andrew ^b   Dotto, G Paolo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CDK inhibitors; Cell cycle; ras oncogene; tumor suppression

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN P27; CALCIUM; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; KERATINOCYTE; MOUSE; MUTANT; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; CELL DIVISION; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALIA; MUS MUSCULUS;

ANIMALS; CALCIUM; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENES, RAS; KERATINOCYTES; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029658030     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.10.23.3065     Document Type: Article

References (57)

1. Alexandrow, M.G. and H.L. Moses. 1995. Transforming growth factor β 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription. Cancer Res. 55: 3928-3932.
2. Brissette, J., C. Missero, S.H. Yuspa, and G.P. Dotto . 1992. Different levels of v-Ha-Ras-p21 expression in primary keratinocytes transformed with Harvey sarcoma virus correlate with benign versus malignant behavior. Mol Carcinogenesis 7: 21-25.
3. Brugarolas, J., C. Chandrasekaran, J. Gordon, D. Beach, T. Jacks, and G. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
4. Calautti, E., C. Missero, P.L. Stein, R.M. Ezzell, and G.P. Dotto. 1995. Fyn tyrosine kinase is involved in keratinocyte differentiation control. Genes & Dev. 9: 2279-2291.
5. Chen, I., P. Jackson, M. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386-388.
6. Cox, L.S. and D.P. Lane. 1995. Tumor suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. BioEssays 17: 501-508.
7. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
8. Dlugosz, A.A. and S.H. Yuspa. 1993. Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C. J. Cell Biol. 120: 217-225.
9. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221.
10. Dotto, G.P., L.F. Parada, and R.A. Weinberg. 1985. Specific growth response of ras-transformed embryo fibroblasts to tumor promoters. Nature 318: 472-475.
11. Dotto, G.P., R.A. Weinberg, and A. Ariza. 1988. Malignant transformation of mouse primary keratinocytes by HaSV and its modulation by surrounding normal cells. Proc. Natl. Acad. Sci. 85: 6389-6393.
12. Dulic, V., E. Lees, and S.I. Reed. 1992. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257: 1958-1961.
13. El-Deiry, W.S., T. Takashi, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
14. Kip1 deficient mice. Cell 85: 733-744.
15. Gu, Y., C.W. Turek, and D.O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20KD regulatory subunit. Nature 366: 707-710.
16. Halevy, O., B. Novitch, D. Spicer, S. Skapek, J. Rhee, G. Hannon, D. Beach, and A. Lassar. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018-1021.
17. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75: 805-816.
18. Hennings, H., D. Michael, C. Cheng, P. Steinert, K. Holbrook, and S.H. Yuspa. 1980. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 19: 245-254.
19. Hinds, P.W. and R.A. Weinberg. 1994. Tumor suppressor genes. Curr. Opin. Genet. Dev. 4: 135-141.
20. Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
21. Jiang, H., J. Lin, S. Zao-zhong, F. Collart, E. Huberman, and P. Fisher. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/C1P1, expression in the absence of p53. Oncogens 9: 3397-3406.
22. Jiang, H., J. Lin, S. Zao-zhong, M. Herlyn, R. Kerbel, B. Weiss- man, D. Welch, and P. Fisher. 1995. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 11: 1855-1864.
23. Kip1) of cyclin-dependent kinase-4 activation. Cell 79: 487-496.
24. Kemp, C.J., L.A. Donehower, A. Bradley, and A. Balmain. 1993. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74: 813-822.
25. Kip1. Cell 85: 721-732.
26. Kranenburg, O., V. Scharnhorst, A. Van der Eb, and A. Zantema. 1995. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J. Cell Biol. 131: 227-234.
27. Lee, M.H., M. Nikolic, C.A. Baptista, E. Lai, L.H. Tsai and J. Massaguè. 1996. The brain-specific activator p35 allows Cdk5 to escape inhibition by p27Kipl in neurons. Proc. Natl. Acad. Sci. 93: 3259-3263.
28. Li, R., S. Waga, G.J. Hannon, D. Beach, and B. Stillman. 1994. Differential effects by the p21 CDK inhibitor on PCNA dependent DNA replication and repair. Nature 371: 534-537.
29. Cipl. Nature 375: 159-161.
30. MacLeod, K.F., N. Sherry, G. Hannon, G. Beach, T. Tokino, K.W. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes & Dev. 9: 935-944.
31. Massaguè, J. 1990. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6: 597-641.
32. Massaguè, J., K. Polyak, M.H. Lee, H. Erdjument-Bromage, A. Koff, J.M. Roberts, and P. Tempst. 1994. Cloning of p27 KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
33. WAF1/Cip1 and terminal differentiation control of normal epithelia. Mol. Cell. Diff. 4: 1-16.
34. Missero, C., S. Ramon y Cajal, and G.P. Dotto. 1991. Escape from TGF-β control and oncogene cooperation in skin tumor development. Proc. Natl. Acad. Sci. 88: 9613-9617.
35. Missero,C., E. Calautti, R. Eckner, J. Chin, L.-H. Tsai, D.M. Livingston, and G.P. Dotto. 1995. Involvement of the cell cycle inhibitor Cip1 /WAF1 and the EIa-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. 92: 5451-5455.
36. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720.
37. Noda, A., Y. Ning, S.F. Venable, O.M. Pereira-Smith, and J.R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211: 90-98.
38. Nourse, J., E. Firpo, W.M. Flanagan, S. Coats, K. Polyak, M.H. Lee, J. Massaguè, G. Crabtree, and J. Roberts. 1994. Interleukin 2-mediated elimination of p27Kip1 cyclin-dependent ki- nase inhibitor prevented by rapamycin. Nature 372: 570-573.
39. Palmer, T.D., R.A. Hock, R.A. Osborne, and A.D. Miller. 1987. Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc. Natl. Acad. Sci. 84: 1055-1059.
40. Pardee, A.B. 1989. G1 events and regulation of cell proliferation. Science 246: 603-608.
41. cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027.
42. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
43. Reynisdottir, R., K. Polyak, A. Lavarone, and J. Massaguè. 1995. Kip/Cip and INK4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes & Dev. 9: 1149-1163.
44. Roop, D.R., D.R. Lowy, P. Tambourin, J. Strickland, J.R. Harper, Balaschak, E. Spangler, and S. Yuspa. 1986. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323: 822-824.
45. Serrano, M., H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. Depinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
46. Sherr, C.J. 1994. G1 phase progression: Cycling on Cue. Cell 79:551-555.
47. 1 cyclin-dependent kinases. Genes & Dev. 9: 1149-1163.
48. Shim, J., H. Lee, J. Park, H. Kim, and E.-J. Choi. 1996. A nonenzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381: 804-807.
49. Shivji, M.K.K., S.J. Grey, U.P. Strausfeld, R.D. Wood, and J.J. Blow. 1994. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr. Biol. 4: 1062-1068.
50. Steinman, R., B. Hoffman, A. Iro, C. Guillouf, D. Liebermann, and M. El-Houseini. 1994. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9: 3389-3396.
51. Waga, S., G.J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578.
52. Weinberg, R.A. and T. Jacks. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13: 4251-4259.
53. Ha oncogene. Cancer Res. 54: 5584-5592.
54. Williams, B.O., E.M. Schmitt, L. Remington, R.T. Bronson, D.M. Albert, R.A. Weinberg, and T. Jacks. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13: 4251-4259.
55. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
56. Yang, Z.Y., N.D. Perkins, T. Ohno, E.G. Nabel, and G.J. Nabel. 1995. The p21 cyclin-dependent kinase inhibitor suppresses tumorigencity in vivo. Nature Med. 1: 1052-1056.
57. CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes &. Dev. 9: 1740-1752.